STEVEN GALVEZ: Open Payments
NPI 1457422016 · GREENSBORO, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,629 in 44 payments from 11 companies in 2025. Trend: 2023 $1,178 · 2024 $1,312 · 2025 $1,629
Food & beverage: $1,629
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $300 |
| Otsuka America Pharmaceutical, Inc. | 7 | $276 |
| Axsome Therapeutics, Inc. | 2 | $236 |
| AstraZeneca Pharmaceuticals LP | 6 | $209 |
| Amgen Inc. | 4 | $168 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $159 |
| Teva Pharmaceuticals USA, Inc. | 2 | $112 |
| Novartis Pharmaceuticals Corporation | 4 | $87 |
| ABBVIE INC. | 2 | $47 |
| Dexcom, Inc. | 1 | $20 |
Products named: REXULTI, Wegovy, Auvelity, JARDIANCE, BREZTRI, AUSTEDO XR, LEQVIO, AIRSUPRA.
Industry payments across AL — which companies pay providers there.
